CHINA — Angel Yeast, a prominent player in the yeast manufacturing sector, has officially commenced production of its plateau probiotics project in Xizang, marking a significant advancement in the company’s biotech transformation strategy.
This initiative aims to establish local and industrialized production of probiotics, which have vast applications across the food, healthcare, and agriculture industries.
The new probiotics line focuses on three primary industrialised strains. The first, Lactobacillus plantarum S2, is known for its strong acid-producing capabilities and effective fermentation results, making it suitable for food and agricultural applications.
The second strain, DB-8, is valuable in dairy production. It enhances yogurt with a natural tomato flavor without the need for additives.
Lastly, Streptococcus thermophilus plays a crucial role in preventing yogurt from further acidification, thus preserving its taste over time.
He Xinzhang, the general manager of Angel Yeast’s subsidiary in Xizang, shared insights into the extensive research and development efforts that preceded this launch.
“For three years, our R&D team faced the challenges of altitude sickness while visiting herdsmen’s families to collect dairy products. We traveled to high-altitude areas, chasing yaks and gathering cow dung, to conduct a comprehensive microbial resources census,” he explained.
This rigorous process resulted in collecting and preserving over 1,800 bacterial strains, which were meticulously evaluated to identify those suitable for industrialisation.
He emphasized the competitive edge gained through this initiative, stating, “Now we not only have the patent-licensed probiotic strains but also possess independent intellectual property rights over the production process. This combination significantly strengthens our market position.”
Furthermore, Angel Yeast is committed to developing a local talent pipeline in management, finance, and equipment expertise as the probiotics project expands.
The newly established Xizang Angel Zhufeng Biotechnology Co., Ltd. boasts full independent rights over key strains and production processes.
The facility is characterized by a fully digitalized and automated workshop, which enables automatic control, enclosed conveying, comprehensive digital management, and quality tracing across all operational sections.
Looking forward, Angel Yeast is set to pursue its strategic roadmap for biotech transformation, leveraging innovation as a key growth driver.
The company is developing four crucial biotech sectors: microorganisms and cell cultures, biocatalysis and enzymes, biomaterials, and biotechnology services.
In addition, it aims to promote the applications of synthetic biology across various fields, including healthcare and bio-agriculture.
This expansion into probiotics represents a pivotal moment for Angel Yeast. It aligns with broader trends in the biotech industry, which is experiencing an increasing demand for sustainable and health-oriented products.
He noted, “Our efforts in Xizang are not just about production; they are about creating a sustainable future through innovative biotechnology.”
Sign up to receive our email newsletters with the latest news updates and insights from Africa and the World HERE.
